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Introduction: Autoimmune diseases such as systemic lupus erythematosus, rheumatoid
arthritis, and multiple sclerosis affect millions of people worldwide. Interferon regulatory
factor 5 (IRF5) contains polymorphisms associated with these autoimmune diseases.Two
of these functional polymorphisms are found upstream of the IRF5 gene. rs2004640, which
is a single nucleotide polymorphism and the CGGGG insertion/deletion (indel) were studied.
IRF5 uses four different promoters for its four first exons: 1A, 1B, 1C, and 1D. Each promoter
was analyzed, including functional differences due to the autoimmune-risk polymorphisms.
Results: IRF5 promoters were analyzed using ChIP-Seq data (ENCODE database) and the
FactorBook database to define transcription factor binding sites.To verify promoter activity,
the promoters were cloned into luciferase plasmids. Each construct exhibited luciferase
activity. Exons 1A and 1D contain putative PU.1 and NFkB binding sites. Imiquimod, a
Toll-like receptor 7 (TLR7) ligand, was used to activate these transcription factors. IRF5
levels were doubled after imiquimod treatment (p<0.001), with specific increases in the
1A promoter (2.2-fold, p=0.03) and 1D promoter (2.8-fold, p= 0.03). A putative binding
site for p53, which affects apoptosis, was found in the promoter for exon 1B. However,
site-directed mutagenesis of the p53 site showed no effect in a reporter assay.
Conclusion:The IRF5 exon 1B promoter has been characterized, and the responses of each
IRF5 promoter to TLR7 stimulation have been determined. Changes in promoter activity
and gene expression are likely due to specific and distinct transcription factors that bind to
each promoter. Since high expression of IRF5 contributes to the development of autoim-
mune disease, understanding the source of increased IRF5 levels is key to understanding
autoimmune etiology.
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INTRODUCTION
Alternative splicing is a method of making different transcripts
from one genomic region. One type of alternative splicing involves
the use of multiple first exons. This is termed alternative pro-
moter splicing, since each first exon must have its own promoter.
Alternative promoter splicing occurs in around half of human
genes (1).
The gene interferon regulatory factor 5 (IRF5) is a transcrip-
tion factor which controls immune signaling, cytokine expression,
the cell cycle, and apoptosis (2–5). It exhibits alternative promoter
splicing and has four different first exons that are currently known.
The start codon for IRF5 is in exon 2, therefore the use of different
first exons does not directly alter the protein sequence. Instead the
four alternative promoters are four pathways to make the same
protein. The first exons are 1A, 1B, 1C, and 1D.
The IRF5 gene contains several GWAS-identified polymor-
phisms associated with autoimmune diseases. Among them, most
do not have an assumed effect. Although IRF5 contains several
polymorphisms associated with autoimmunity, only four have
been identified as functional polymorphisms (6). Two of these are
in the promoter or untranslated regions of IRF5 where the poly-
morphisms may have a direct effect on IRF5 expression: a single
nucleotide polymorphism (SNP) near exon 1B called rs2004640,
and a copy-number variant near exon 1A called rs77571059
(Figure 1). The rs77571059 polymorphism is an insertion/deletion
(indel) of 5 bp, and is commonly referred to as a CGGGG indel.
This study examines the promoters of IRF5, with information
on how these two functional polymorphisms play a role in IRF5
expression. A general trend of these polymorphisms is to increase
levels of IRF5.
The rs2004640 SNP is a G or T polymorphism near the 3′ end
of exon 1B. The SNP is within the splice junction, such that when
the G allele is present, the splice junction is not recognized and
exon 1B cannot be spliced onto exon 2 (8). Unspliced transcripts
are usually targeted by non-sense mediated decay (9). The risk T
allele at this locus is associated with systemic lupus erythematosus
(SLE) in multiple ethnic groups (8, 10–13) rheumatoid arthritis
(14, 15), systemic sclerosis (16), multiple sclerosis (17), ulcerative
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FIGURE 1 | Interferon regulatory factor 5 mRNA and the position of the
rs2004640 SNP and CGGGG indel. (A) rs2004640 is at the splice acceptor
site for exon 1B, and the CGGGG indel is 64 bp upstream from the
transcription start site for exon 1A. The genomic region of IRF5 is drawn to
scale, but with introns reduced in size 10:1. The protein coding and
untranslated regions are shown above. Only one first exon is used per RNA
transcript; therefore each first exon corresponds to the untranslated region for
that transcript. (B) The position of the rs2004640 SNP on pre-mRNA. Before
splicing, the messenger RNA has either a U (encoded by the risk T allele) or
G. The colored letters shown in the WebLogo (the nucleotide stacks of varying
heights represent the consensus recognition sites for the spliceosome. The
height of the stack represents how often those nucleotides are found at that
position, and thus the high GT represents a strong preference for recognizing
GT at the intron boundary. This matches in the risk T allele (GT at the intron
boundary), but not the protective allele (GG at the intron boundary). A person
homozygous for the protective allele cannot splice IRF5 mRNA that begins
with exon 1B. Instead of a functional protein, the resultant mRNA would
encode a non-functional protein and be targeted for non-sense mediated
decay. Splice junction WebLogos are from Stephens and Schneider (7).
(C) The CGGGG indel is an insertion/deletion of a CGGGG repeat upstream of
exon 1A, and it is part of exon 1A’s promoter. When there are four copies,
additional SP1 transcription factors (which bind to GGCGG) can bind to the
promoter, altering transcription levels. UTR, untranslated region; SNP, single
nucleotide polymorphism.
colitis (18), and Sjögren’s syndrome (19). Autoimmune-risk hap-
lotypes that include rs2004640 exhibit high IRF5 levels (6, 20), as
well as high levels of IFNα and TNFα (21, 22).
The CGGGG indel (rs77571059) is found 64 bp upstream of
the transcription start site for exon 1A. Each allele has either three
(3×) or four copies (4×) of the CGGGG repeat sequence. The
4× copy-number variant allows binding of additional SP1 tran-
scription factors (23). This 4× variant is associated with SLE (10),
Sjögren’s syndrome (24), multiple sclerosis (17), Crohn’s disease
and ulcerative colitis (18), and acute coronary syndrome (25). The
CGGGG 4× variant is associated with increased expression of IRF5
itself (23), as well as TNFα, IL-12p40, IL-8, IL-1b, and IL-10 (22).
Interferon regulatory factor 5 exons 1A, 1B, 1C, and 1D each
have a distinct transcriptional start site, and as is the case with
every first exon, each exon 1 of IRF5 has its own promoter. IRF5’s
four promoters have not been thoroughly characterized, although
previous studies on the 1A and 1C exons’ promoters revealed
that they are controlled in part by an IRF element (IRFE) and
an interferon stimulatory response element (ISRE), respectively
(26). Herein, we identify and characterize a putative promoter for
exon 1B, and hypothesize that the 1B promoter would be active
and regulated by stimuli that activate IRF5. We further hypothesize
that the 1B promoter would be regulated by p53.
Autoimmune diseases are caused by environmental triggers in
those with a genetic propensity. Increases in IRF5 expression due
to these promoter polymorphisms could lead to an autoimmune-
risk state. A hallmark of lupus and those at genetic risk for lupus
is the presence of heightened levels of interferon and interferon-
response genes; the interferon signature (27). IRF5 is a key gene in
the interferon response to viral infection. IRF5 is a transcription
factor whose activation leads to the interferon signature and the
control of multiple genes involved in inflammation and immunity
(28). It is primarily expressed in B cells, monocyte-derived cells,
and plasmacytoid dendritic cells (pDCs) (2).
Frontiers in Immunology | Molecular Innate Immunity November 2013 | Volume 4 | Article 360 | 2
Clark et al. Activity of four IRF5 promoters
For SLE, an environmental trigger is likely to be Epstein–Barr
virus (EBV) infection (29, 30). EBV infection affects IRF5 and
IRF7 signaling, and has been associated with lupus through several
different mechanisms (30–32). Interestingly, EBV infection alters
IRF5 splicing to produce a dominant negative variant, suppress-
ing the interferon response (33). For these studies, EBV-infected B
cells are used, because cells with the appropriate genotypes can be
immortalized and used in multiple experiments. As B cells, these
cells are relevant to autoimmune disease and express IRF5. The
incorporation of EBV into the model cells means that our results
must be interpreted with caution, as it is possible that the major
effects of these risk polymorphisms regulate or alter EBV infec-
tion, not IRF5 directly. These results must therefore be interpreted
with caution. However, if it is found to be the case that these
IRF5 polymorphisms affect EBV infection, that would likely pro-
vide even more exciting directions to pursue given the potential
relationship between EBV infection and lupus.
RESULTS
IRF5’S FOUR PROMOTERS
Interferon regulatory factor 5 uses one of four first exons for each
molecule of mRNA – 1A, 1B, 1C, or 1D. Whether or not one of
the four first exons of IRF5 would be actively transcribed depends
on the cellular transcription factors that are able to bind it. A
putative IRF5 exon 1B promoter sequence was identified by using
the encyclopedia of DNA elements chromatin immunoprecipita-
tion sequencing (ENCODE ChIP-Seq) data set (34). This analysis
includes a list of transcription factors known to bind to the puta-
tive promoter sequence. An analysis of the promoters for each
of the other three first exons of IRF5 was performed using the
same database. This list represents results from many experiments
which show transcription factors that bind to this genomic region
of DNA (Figure 2A).
The transcription factors listed have also been associated
with specific binding sites. WebLogos, which visualize consensus
A B
C
FIGURE 2 | Promoter analysis of each first exon of IRF5. (A) ENCODE data
shows results of ChIP-Seq analyses in the promoter region of IRF5. (B) The
consensus search terms generated from FactorBook, with the TCF12
consensus binding site as an example (35). This data was used to manually
define the nucleotide search terms shown. (C) The final analysis of potential
binding sites is shown along the genomic DNA promoter sequences, with
color-coded boxes representing the binding sites or transcription factors
shown in the key. AP, activator protein; BRE, B-response element; CTCF,
CCCTC binding factor; TCF, transcription factor; EBF, early B cell factor; IRF,
interferon regulatory factor; NFκB, nuclear factor kappa light chain enhancer
of activated B cells; PAX, paired box; PU, purine rich; SP, specificity protein;
STAT, signal transducer and activator of proteins; TATA, thymidine adenine.
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binding sites (36), were generated de novo for each ENCODE
transcription factor tested, and compiled in the online database
FactorBook (35). The consensus sites were converted manually
into an ambiguous DNA code search term, where for example W
(weak) represents an A or a T nucleotide (Figure 2B). The consen-
sus search term was then used to search the proximal promoters
(∼200 bp upstream from the +1 sites) to encounter a proposed
binding site. Consensus search term screening was performed
using MEGA (37).
Several transcription factors’ binding sites were found in
the regions upstream of transcription start sites (Figure 1C).
The start sites were taken from reference sequences for exons
1A, 1B, and 1C, and the sequence for variant 12 of IRF5
for exon 1D (no reference sequence exists at present for exon
1D). The source sequences are GenBank IDs NM_002200.3,
NM_032643.3, NM_001098627.2, and EU258897.1 for exons 1A,
1B, 1C, and 1D, respectively. The workflow and results are
shown in Figure 2, with transcription factor 12 (TCF12) as an
example.
EACH IRF5 PROMOTER EXHIBITS TRANSCRIPTIONAL ACTIVITY
The promoters for the four first exons of IRF5 contain different
potential transcription factor binding sites. The 1A promoter con-
tains putative binding sites for paired box 5 (PAX5), PU.1, SP1,
and TCF12 which binds to enhancer boxes (E boxes). An extra
SP1 binding site appears in those with the CGGGG 4× indel.
Exon 1B’s promoter was the only IRF5 promoter with a p53 bind-
ing site. This is discussed in more detail below. 1B also has SP1,
TCF12, IRF4, and early B cell factor (EBF) sites. The 1C promoter
was the only promoter with STAT2, activator protein 1 (AP1),
and Myc binding sites; it also has SP1 and IRF4 sites. The 1D
promoter evaluation showed potential binding sites for only four
transcription factors: SP1, CCCTC binding factor (CTCF), IRF4,
and NFκB.
To determine activity levels of each promoter, they were cloned
using PCR and inserted into luciferase reporter plasmids. In addi-
tion to the 1B, 1C, and 1D promoters, there are two distinct
versions of the 1A promoter, representing the two rs77571059
polymorphisms. One has the 4× variant of the CGGGG indel
(1Arisk), and the other has the 3× variant (1Aprotective). The 1B
promoter was cloned using nested PCR to avoid an inverted repeat
sequence located∼2 kbp upstream. The inverted repeat is 1.8 kbp
in length, and the two copies have 82.8% identity (34).
A luciferase assay was performed using the pGL4 plasmid.
The promoters of IRF5 were inserted upstream of the luciferase
gene and promoter activity was evaluated by measuring lumines-
cence. The activity levels of the promoters were analyzed in several
cell types since distinct transcription factors would be active in
different cell types. Three types of immune cells were used: lym-
phoblastoid cell lines (LCLs), EBV-transformed human B cells
that were generated from three healthy volunteers; U937 cells,
a commercially available human monocyte cell line; and Jurkat
cells, a commercially available human T cell line. Jurkat cells were
used as the negative control, since T cells do not express high
levels of IRF5. Cells were electroporated with each of the IRF5
promoter luciferase plasmids. A second plasmid, which expresses
enhanced green fluorescent protein (eGFP), was cotransfected as
a transfection control for each construct (38). Values for luciferase
expression were then normalized to the fluorescence level to
account for transfection efficiency.
Luciferase assay results showed that the 1A promoters (1Arisk
and 1Aprotective) demonstrated significantly higher transcriptional
activity than the other three promoters in LCL and Jurkat cells
(p= 0.0009 and p= 0.016, respectively) (Figure 3). As expected,
FIGURE 3 | Interferon regulatory factor 5 promoter activity in immune
cells. The luciferase plasmids were transfected by electroporation of three
cell types: LCL, U937 cells, and Jurkat cells. A control GFP-encoding
plasmid was also used in each sample to normalize transfection efficiency.
ANOVA analysis revealed statistically significant variation between groups
(p=0.014); therefore t -tests were used to determine where the variation
was found. The levels of transcription were significantly lower in Jurkat cells
compared to LCL and U937 cells (p<0.01). IRF5 is not highly expressed in
T cells such as Jurkat cells, but is normally expressed in B cells and
monocytes (39). The 1A promoters (1Arisk and 1Aprotective) displayed higher
activity than the 1B, 1C, or 1D promoters in LCL and Jurkat cells
(p=0.0009 and p=0.016, respectively). In LCLs the 1Arisk promoter activity
was higher than 1Aprotective promoter activity (p=0.019). The putative 1B
promoter acted like the 1A promoter in that expression was significantly
higher in LCLs than in Jurkat cells (p=0.027). LCL, lymphoblastoid cell line;
RLU, relative luminescence units; RFU, relative fluorescence units. In some
samples, the first exon was not detectable, which is why there is some
variation in sample number.
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expression from all IRF5 promoters was significantly lower
(p< 0.01) in Jurkat cells when compared to U937 or LCL cells.
When comparing LCL to U937 cells, there was no significant
difference in IRF5 promoter activity (p= 0.38).
The autoimmune-risk polymorphisms affected the activity of
the promoters. In LCLs the 1Arisk promoter activity was signifi-
cantly higher than 1Aprotective promoter activity (p= 0.019). The
1B promoter, which is only relevant when the risk allele rs2004640
is present, showed activity in LCLs and U937 cells, indicating
that it is an active promoter in the same cell types as the other
promoters.
THE 1A AND 1D PROMOTERS ARE AFFECTED BY TLR7 LIGATION
The levels of IRF5 expression increase due to several signaling
pathways, one of which is the Toll-like receptor 7 (TLR7) pathway.
Endosomal TLRs such as TLR7 require the ligand to first be endo-
cytosed into the cells, and then merged with the endosome that
contains TLR7. Most endosomal TLRs bind to nucleic acids.
Toll-like receptor 7 ligation is an important method of acti-
vation for pDCs (40, 41). pDCs can produce large amounts of
interferon alpha in response to immunostimulatory molecules
such as nucleic acids. This is an important activation pathway
in autoimmune disease (42). Single stranded RNA is the natural
agonist for TLR7. TLR7 can also be activated by small synthetic
compounds such as the imidazoquinolines, namely imiquimod
and resiquimod. Imiquimod is a TLR7 ligand and resiquimod
is a ligand for TLR7 and TLR8 (43). Imiquimod is used clini-
cally as a topical cream as a form of treatment for genital warts
and certain cancers. It activates the immune system, recruiting
inflammatory mediators to kill the virus-infected or cancerous
cells (44).
To verify that imiquimod treatment was stimulating the cells
through TLR7, gene expression of interferon-response genes and
cytokine gene expression were monitored using real-time PCR.
Imiquimod stimulation led to significantly increased expression
of the interferon-induced genes CCR7 and NOXA, while expres-
sion of the calreticulin was not significantly affected (Figure 4).
Expression of the genes for the cytokine IL-6 was substantially
upregulated (71-fold increase, p= 0.028). IL-6 expression is a
common readout for stimulation through TLR7 (45, 46). Expres-
sion of the cytokine IL-10 is also significantly, though slightly,
increased (1.5-fold, p= 0.038) after treatment with imiquimod
(Figure 4). These results indicate that imiquimod treatment did
in fact stimulate the cells.
Imiquimod treatments were performed to determine the effects
of stimulation on the activity of each IRF5 promoter. First exon-
specific quantitative PCR was used to determine changes in the
levels of each first exon after imiquimod stimulation. Cells were
treated with imiquimod at 25µg/ml for 24 h, and then cDNA
was prepared from an RNA extract of treated cells. This was
done for LCLs generated from 20 healthy individuals. As expected,
IRF5 levels increased when cells were treated with imiquimod –
a 1.9-fold increase when normalized to the housekeeping gene,
β-glucuronidase (β-GUS) (Figure 5A).
The amounts of each first exon were also measured and com-
pared to β-GUS by quantitative PCR. Several samples yielded
undetectable levels of first exon transcripts, and were thus not
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FIGURE 4 | Imiquimod stimulates LCLs to express cytokines and
interferon-response genes. LCLs were generated by EBV infection of cells
from healthy volunteers. Cells were treated with imiquimod. (A) Expression
of the interferon-response genes CCR7, NOXA, and Calreticulin were
measured using SYBR Green real-time PCR. The figure shows the fold
increase in gene expression after imiquimod stimulation for each gene.
CCR7 and NOXA were significantly upregulated after imiquimod stimulation
(p=0.008 and p=0.003, respectively). (B) Expression of cytokine RNA
was measured using SYBR Green real-time PCR. IL-6 expression was
upregulated by 71-fold after imiquimod stimulation (p=0.028). IL-10
expression was also significantly upregulated (p=0.038), although to a
much lesser extent, at 1.5-fold. N =12 for each experiment.
included in the analysis, resulting in the variation in sample num-
ber noted in Figure 5. The levels of exons 1A and 1D increased by
at least twofold after treatment with imiquimod when compared
to β-GUS (Figure 5B).
The effect of the rs2004640 polymorphism on imiquimod stim-
ulation on was examined using real-time PCR. LCLs with risk or
protective genotypes were stimulated with imiquimod, and the
change in expression of interferon-stimulated genes was compared
between risk and protective cells. IRF5 expression was higher in
risk cells by nearly 1.7-fold (p-0.021). CCR7 did not increase as
much after imiquimod stimulation in the risk cells compared to
the protective (0.77-fold, p= 0.05). However, the risk cells demon-
strated a small increase in NOXA expression after imiquimod
stimulation,and the Calreticulin levels decreased less (by 1.35-fold,
p= 0.05) in the risk cells than in the protective (Figure 6). These
results show a small, but consistent increase in responsiveness to
imiquimod stimulation in the cells with the risk allele.
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FIGURE 5 | Imiquimod caused increased IRF5 transcription through
exons 1A and 1D. All mRNA levels were measured in LCLs generated from
healthy individuals. Levels were determined by TaqMan-based quantitative
PCR using the 2−∆∆CT method. (A) The levels of IRF5 were 1.9-fold higher in
treated cells (p=0.0002). (B) The levels of exon 1A increased 2.2-fold
(p=0.030) and exon 1D increased by 2.8-fold (p=0.033). All fold-increase
values were normalized to the β-GUS housekeeping gene. The numbers in
parentheses indicate the sample size. Analysis of variance was performed
including each first exon and stimulation state as groups. This analysis
revealed statistically significant variation (p<0.0001). Statistical significance
between individual groups was determined by paired t -test. IRF, interferon
regulatory factor.
The effect of EBV infection on IRF5 expression and imiquimod
stimulation were analyzed. Ramos cells, a B cell line that is simi-
lar to LCL but is EBV negative, were stimulated with imiquimod
and expression of IRF5 was compared to IRF5 expression in LCLs.
After two experiments, there was a <1.2-fold difference in IRF5
expression between the EBV positive and EBV-negative cell lines.
After imiquimod stimulation, there was similarly only a very small
difference between the EBV positive LCL and EBV-negative Ramos
cells (Figure 6B).
THE rs2004640 SNP’S ROLE IN p53 BINDING AND ACTIVATION
Mutagenesis of the 1B promoter p53 binding site did not alter
transcriptional activity.
The promoter analysis described above revealed a potential p53
binding site. p53 binds as a tetramer to two copies of the sequence
rrrCwwGyyy, with a spacer of 0–13 nt between the copies (189).
A close match to this sequence was found in the 1B promoter
(Figure 7B). This is suggestive because of the potential role IRF5
may play in apoptosis dysregulation in SLE. IRF5 is also proapop-
totic in a p53-independent manner (47), and thus if p53 activates
IRF5, apoptosis levels would be additively altered. Should p53 can
control the 1B promoter, apoptosis would be altered in rs2004640
risk cells because the 1B promoter is only used in cells with the
rs2004640 risk allele.
To test whether activated p53 protein can indeed bind to the
p53 binding site, the plasmid which contains the 1B promoter was
mutated using site-directed mutagenesis. Mutations were made
to the wild-type sequence such that p53 should not be able to
bind. The consensus binding site contains four conserved C or
G bases which were mutated to A or T on the luciferase plas-
mid (Figure 7B). The wild type and p53-mutant luciferase plas-
mids were transfected by electroporation into three different LCLs
generated from healthy volunteers. After 24 h to allow for plasmid
expression, cells were either treated with etoposide or left untreated
for 48 h. The levels of luciferase activity stayed fairly constant in
the wild-type plasmid when treated with the etoposide. However,
when the p53 binding site was mutated, thus inhibiting binding
of p53, there is an slight, but non-significant increase in activ-
ity when treated with the etoposide versus being left untreated
(Figure 7A). This finding suggests that if p53 does in fact bind
to the IRF5 exon 1B promoter, it is likely inhibitory rather than
stimulatory.
DISCUSSION
The CGGGG indel polymorphism within the 1A promoter has
previously been shown to alter transcription factor binding. When
cells have the 4× variant, an additional SP1 binding site is cre-
ated. This has been shown to increase IRF5 in PBMCs (48), but
decrease 1A-specific IRF5 transcripts in thymic cells (49). Both
versions of the 1A promoter showed activity in HEK293T cells
and Raji cells. As expected, SP1 sites were found in our analysis
of the 1A promoter, including an extra SP1 binding site in those
with the CGGGG 4× indel. SP1 is active during development, cell
growth, apoptosis, differentiation, and immune and DNA damage
responses (50).
The 1A promoter has a PAX5 binding site, a gene that activates
B cells at early, but not late stages of development (51). There is an
E box, and TCF12 is a member of the basic helix-loop-helix group
of transcription factors which binds to E boxes (52). TCF12 was
shown to bind somewhere in the promoter region of IRF5 in the
ENCODE dataset (34), and the putative E box in 1A’s promoter is
a likely site. TCF12 is known to be expressed in B cells and T cells
(39). A PU.1 site is in the 1A promoter as well; PU.1 activates gene
expression during B cell development and in myeloid cells (53).
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FIGURE 6 |The 2004640 risk allele affects responsiveness toTLR7
stimulation. (A) LCLs with either risk or protective genotypes were treated
with imiquimod to stimulate TLR7. Expression of interferon-response genes
before and after stimulation was compared using SYBR Green real-time
PCR. RNA input was normalized for each sample using the housekeeping
gene GAPDH. Increase after imiquimod stimulation for risk and protective
cells is shown. IRF5 expression is higher after imiquimod stimulation in the
risk cells, by 1.67-fold (p=0.021). Although Calreticulin expression
decreases in both the risk and protective cells, it does so less in the risk
cells (p-0.05). CCR7 increases less in the risk cells after imiquimod
treatment (p=0.05) N =12 (B). EBV status does not dramatically effect
IRF5 levels. IRF5 expression was compared between LCLs and Ramos
cells, a Burkitt’s lymphoma-derived B cell line that is EBV negative. IRF5
levels were not dramatically different between cell lines N =2.
The 1A promoter showed increased activity when cells were
stimulated with the TLR7 agonist imiquimod. This may be
through the PU.1 site through IRF7. IRF7 is known to be acti-
vated by TLR7 (54), and PU.1 binds to a similar GAAN(N)GAA
motif to IRFs. Further work is necessary to determine in which
cell types or with which stimuli the 1A promoter is most active,
and in what instances the CGGGG 4× variant alters this activity.
A previous report by Mancl et al. evaluated the 1A and 1C
promoters (26). The 1A promoter was activated by herpes sim-
plex, Newcastle disease and vesicular stomatitis viruses in PBMCs,
Daudi, and THP-1 cells; respectively; as evidenced by increased
transcription of IRF5. A luciferase reporter gene assay also showed
that IRF5’s 1A promoter is constitutively active and contains an
IRFE consensus binding site. However, the promoter region used
was a 596-bp region determined by a 5′ rapid amplification of
cDNA ends (5′RACE) experiment and is 939 bp upstream of the
GenBank reference sequences for exon 1A, and even extends past
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FIGURE 7 | Interferon regulatory factor 5 1B promoter activity is not
regulated by direct p53 binding. (A) Different LCLs generated from
healthy volunteers were electroporated with the 1Bwt or the 1Bp53*
promoter luciferase plasmid. Cells were treated with 0.5 mM etoposide or
left untreated. Despite the presence of a putative p53 binding site, DNA
damaging treatment did not affect promoter activity; neither did mutation of
the p53 site. (B) The putative p53 binding site in IRF5’s exon 1B promoter,
with a WebLogo of the p53 consensus binding site (29) to indicate
important bases and matches. The height of the base represents the
frequency of that nucleotide. Site-directed mutagenesis was performed to
mutate the binding site at the critical C and G bases as shown. UV,
ultraviolet; wt, wild type; *, mutant.
the 1D exon by 714 bp. The results of their luciferase assay can-
not therefore be compared with the promoter analysis performed
in this work. This work narrows the DNA regions studied and
separates them into each of the four unique promoter elements,
demonstrating that each are active promoters. This work also con-
firms that the 1A promoter is the strongest and is activated by
imiquimod, and that the 1D promoter is also strongly activated by
this stimulus.
The ability of a cell to use and splice the 1B exon is indepen-
dent of its promoter usage. The 1B promoter is active in persons
with both the risk and protective polymorphisms at rs2004640,
yet the protective sequence would result in a non-sense transcript,
as splicing would not be possible. The risk T allele allows for the
exon 1B transcript to be spliced onto exon 2 and this is evidenced
by the correlation between the risk T allele and increased levels of
both IRF5 and exon 1B usage. The effects of the ability to use the
1B promoter can also be seen in the increased responsiveness of
the cells containing the risk allele to imiquimod.
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Interferon regulatory factor 5’s 1B promoter was predicted
to contain a p53 binding site. The only promoter tested which
increased in activity after inducing DNA damage was the 1B pro-
moter. The others showed a reduction in luciferase activity (data
not shown). The mutated version of the 1B promoter, which con-
tained an altered p53 binding site, showed a slight increase in
luciferase activity instead of a decrease, likely suggesting that any
p53 binding to this promoter region is inhibitory. The 1B pro-
moter contains SP1, IRF4, TCF12, and EBF binding sites. EBF is a
B cell-specific transcription factor (55). Further work is necessary
to reveal the stimuli or cell types that use the 1B promoter, as well as
the combinations of transcription factors that drive transcription.
During cloning experiments dealing with exon 1B and its
promoter, several sequencing reactions showed <100% sequence
identity to the target. It was soon discovered that the primers were
annealing to an upstream inverted repeat sequence. This repeat
necessitated nested PCR for cloning the 1B promoter. The repeat
length is 1.8 kbp, and the two copies have 82.8% identity (56). The
function of this repeat is unknown, but repeated sequences can act
as decoys for transcription factors, lowering transcription of the
intended target (57).
Usage of exon 1C is lower in cells with the rs2004640
autoimmune-risk factor. The 1C promoter contains putative SP1,
IRF4, and EBF sites. It was the only promoter with AP1, Myc, and
STAT2 binding sites. AP1 is a heterodimer of Fos and Jun proteins,
among others, which are common in immune signal transduction
(58). Myc is a proto-oncogene, and is essential for B cell prolifera-
tion (59). STAT2, when complexed with STAT1 and IRF9, is known
to be activated by type I interferon (60). The STAT2 binding sites
agree with a previous report on the 1C promoter of IRF5 by Mancl
et al. which said the promoter is interferon responsive (61). The
current analysis identified the same STAT2 binding site in the 1C
promoter. The difference in the two analyses is the assumed place-
ment of the initiation site. The analysis by Mancl et al. uses 5′RACE
to determine the initiation site and they calculate the STAT2 bind-
ing site is 96 bp downstream of that transcription initiation site.
According to our initiation site – taken from the GenBank refer-
ence sequences which use exon 1C – the site was 47 bp upstream
of the initiation site. Also of note, cells treated with imiquimod
had lower 1C levels in proportion to the total IRF5.
Usage of exon 1D is lower in cells with the rs2004640 T allele and
in cells with the CGGGG 4× allele. The 1D promoter evaluation
showed only four transcription factors’ binding sites: CTCF, IRF4,
NFκB, and SP1. NFκB is a target of TLR7 (62), and thus the pro-
moter should be activated by imiquimod treatment. This was the
case, and the 1D promoter nearly tripled in usage after imiquimod
treatment. The IRF5 promoter analysis also showed a CTCF bind-
ing site. It is interesting that the 1D promoter is the furthest exon in
the 5′ direction, and has putative CTCF sites, since CTCF is known
to block the spread of CpG methylation by acting as an insulator
(63). This may keep the other first exons – which are downstream
and have high GC content – free from heterochromatin.
Interferon regulatory factor 5 is proapoptotic in a p53-
independent manner (64, 65). This does not preclude modulation
by p53, and a p53 enhancer site in exon 2 of IRF5 has been shown
to activate IRF5 (66). p53 is a main regulator of apoptosis. Exon
1B’s promoter was the only one with a putative p53 binding site,
and cells with the rs2004640 risk T allele are the only cells that can
use exon 1B. Also, p53 can act as both a repressor and activator
of transcription depending on local factors (67). However, in our
assay, p53 did not significantly regulate the 1B promoter.
Epstein–Barr virus infection is a necessary complicating factor
when using LCLs as B cell lines. This is especially important since
EBV has been shown to affect IRF5 function (33, 68). The effect
of EBV in this study was limited by using EBV-infected LCLs as
both our risk and protective cell lines. Since cell lines of both geno-
types are transformed with EBV, the differences observed should
be comparable and the effect of EBV excluded. However, given
the importance of EBV infection in IRF5 activity and the devel-
opment of lupus, viral effects cannot be simply discounted. There
is a chance that differential effects of the risk polymorphisms on
EBV infection processes are affecting IRF5 activity. These effects
would be difficult to differentiate from direct effects on IRF5 activ-
ity. Either way, however, the results would be interesting and merit
further investigation.
Autoimmune diseases are complex, multifactorial disorders
with both genetic and environmental influences. The promoter
variations examined in these experiments are strongly linked to
risk for autoimmune diseases, including lupus, multiple sclero-
sis, and rheumatoid arthritis. Despite much effort, there has not
been a dramatic effect associated with these polymorphisms, or
really, most of the polymorphisms associated with autoimmune
disease. Rather than diminishing their importance, however, the
somewhat small effects observed here speak to the fine balance of
the immune system. It is likely that even relatively small changes
in gene regulation can lead to an imbalance in tolerance or activa-
tion of immune cells. Also, these genes are intertwined with other
pathways and systems to provide a complex fabric controlling the
level of immune responsiveness.
MATERIALS AND METHODS
PLASMID CONSTRUCTION AND LUCIFERASE ASSAY
All vectors were sequenced to confirm the proper sequence. The
plasmid pMax-GFP (Clontech) expresses the eGFP fluorescent
protein, and it was used to measure transfection efficiency. Elec-
troporations were performed using a Nucleofector device (Lonza).
The electroporation buffer was 5 mM KCl, 15 mM MgCl2, 15 mM
HEPES, 140 mM Na2HPO4, pH 7.2. Transfected cells were lysed
and assayed for fluorescence levels before assaying luciferase activ-
ity using the Luciferase Assay System (Promega) on a Fusion
αHT plate reader (Packard). Luciferase activity was evaluated in
proportion to the transfection efficiency.
CELL LINES
Peripheral blood samples were obtained from healthy volunteers
after informed consent following a protocol approved by the IRB
at Brigham Young University. Peripheral blood mononuclear cells
were isolated using lymphocyte separation medium (Mediatech).
These cells were induced to form LCLs by incubation with EBV
(B95-8 strain) and 2 ng/ml cyclosporin A (Tocris Biosciences).
U937 and Jurkat cells were a kind gift from Dr. Kim O’Neill. Cell
lines were maintained in RPMI (Sigma) with 10% fetal bovine
serum (PerBio) with penicillin/streptomycin/amphotericin (Cal-
biochem) at 5% CO2 and passaged at least weekly.
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GENOTYPING OF VOLUNTEERS AND FORMATION OF PAIRED SAMPLES
Genomic DNA was extracted (Qiagen) from peripheral blood
mononuclear cells and genotyped using TaqMan reagents Applied
Biosystems (ABI) on a StepOnePlus real-time PCR machine (ABI)
at the rs2004640 SNP (ABI SNP Assay C9491614). Homozygous
risk or protective individuals were matched by gender and ethnic-
ity. Heterozygotes were not included in the study. The primers and
PCR conditions are in Table A1 in Appendix.
CELL TREATMENTS
The TLR7 ligand imiquimod (R-837) was used to stimulate cells
for some experiments. Cells were treated for 24 h with 25µg/ml
imiquimod (InvivoGen). cDNA preparation, quantitative PCR,
primers, probes, and conditions are described elsewhere in the
Section “Materials and Methods.” Etoposide was used at 0.1 and
1 mM concentrations and applied for 48 h. 5FU was used at
1.5 mg/ml, and the activating antibodies to TRAIL and Fas were
used at 1 and 5µg/ml, respectively. All treatments used 106 cells
per milliliter.
cDNA LIBRARIES AND PCR
About 8× 106 cells were used for each condition in each exper-
iment. cDNA preparations were made by extracting RNA using
the RNaqueous system (Ambion), followed by DNase treatment
(Promega). One thousand nanograms RNA was per condition was
then reverse transcribed using SuperScript III reverse transcriptase
(Invitrogen Life Technologies). One hundred nanograms cDNA
preparations were used as template for quantitative PCR using
TaqMan reagents (ABI), or SYBR green reagents For gene expres-
sion studies, input RNA levels were normalized using primers to
the housekeeping gene GAPDH for SYBR green experiments and
β-GUS for TaqMan experiments. For cloning of 5′UTRs and pro-
moters the template genomic DNA from Section “Genotyping of
Volunteers and Formation of Paired Samples” was used, with the
NEB High GC PCR kit. Primers were purchased from Integrated
DNA Technologies. Sequences and PCR conditions are available
in Table A1 in Appendix.
SEQUENCING
Plasmid sequencing used purified plasmid DNA and a primer
upstream of the insertion site. Sequencing reactions used Big
Dye terminator reagents and the 3730xl DNA analyzer (ABI). See
Table A1 in Appendix for primers.
STATISTICAL ANALYSIS
A paired t -test was used to compare means for mRNA expres-
sion. Paired t -test was used for luciferase levels. An alpha value
of 0.05 and two-tailed p values were used in all cases. For exper-
iments using more than two comparisons, ANOVA was used to
determine if statistically significant differences were present. Sta-
tistical analysis was performed using Data Analysis Plus software
(Keller Statistics). ANOVA was performed using the CSBJU online
calculator (http://www.physics.csbsju.edu/stats/).
PROMOTER ANALYSIS
An analysis of the promoters for each of the four first exons of
IRF5 was performed using the ENCODE ChIP-Seq data set (34)
for determining actual binding factors on the genomic region, fol-
lowed by determining a consensus site using the WebLogo data
in FactorBook (35). The consensus site was then used to search
the proximal promoters (∼200 bp upstream from the +1 sites)
to encounter a proposed binding site. Consensus site screening
was performed using a custom searches of ambiguous nucleotides
with MEGA (37). This involved searching using the find func-
tion, which allows for searching using the ambiguous nucleotide
code. For example, a search for GAW would highlight both GAA
and GAT.
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APPENDIX
Table A1 | List of primers and PCR conditions.
TAQMAN-BASED QUANTITATIVE PCR PRIMERS
IRF5 exon 2 RT fwd: CCACCTCAGCCCTACAAGAT
IRF5 probe: FAM-TCCAATGGCCCTGCTCCCAC-TAMRA
IRF5 exon 3 RT rev: CTCCTCTCCTGCACCAAAAG
IRF5 1A TaqMan RT fwd: ACGCAGGCGCACCGCAGACA
IRF5 1B RT fwd: AGCTGCGCCTGGAAAGCGAGC
IRF5 1C TaqMan RT fwd: AGGCGGCACTAGGCAGGTGCAAC
IRF5 1D RT fwd: GAGGCTCAGCCCGGATCTGC
IRF5 exon 1 probe: FAM-CCATGAACCAGTCCATCCCAGTGGCTCCCACC-
TAMRA
IRF5 exon 2 common RT rev: TCGTAGATCTTGTAGGGCTGAGGTGGCA
β-Glucuronidase fwd: CTCATTTGGAATTTTGCCGATT
β-Glucuronidase probe: FAM-TGAACAGTCACCGACGAGAG-TAMRA
β-Clucuronidase rev: CCGAGTGAAGATCCCCTTTTTA
Conditions: 52°C, 95°C for 10 min, 52 cycles of (95°C for 15 s, 65°C* for
1 min) with 500 nM primers, 250 nM probe
SYBR green quantitative PCR primers and conditions
GAPDH fwd: TGCACCACCAACTGCTTAGC
GAPDH rev: GGCATGGACTGTGGTCATGAG
CCR7 fwd: GCTCCAGGCACGCAACTT
CCR7 rev: GACCACAGCGATGATCACCTT
Calreticulin fwd: GCAGCAGAAGGGGGTGGTGT
Calreticulin rev: GTCCTGGGGGCAGGGGAGAA
NOXA fwd: GCTGTCCGAGGTGCTCCAGTT
NOXA rev: AGCGTTCTTGCGCGCCTTCT
IRF5 fwd: CCACCTCAGCCCTACAAGAT
IRF5 rev: CTCCTCTCCTGCACCAAAAG
Conditions: 95°C for 10 min, 40 cycles of (95°C for 15 s and 60°C for 1 min)
PROMOTER CLONING PRIMERS
†
IRF5 1A prom fwd: CTGCgctagcCAGGTCAGTGCGGGGC
IRF5 1A prom rev: CCTGagatctACTTCCGCGTCTTGCCGC
Conditions: 94°C for 30 s, 40 cycles of (94°C for 15 s, 62.0°C for 1 min,
68°C for 30 s), 68°C for 5 min
IRF5 1B prom fwd: GCGCgctagcGACAGGTGGGTCCCGGCCGC
IRF5 1B prom rev: GCAGagatctGCGGACCCCGCCCTACTCCA
Nested PCR first round: IRF5 1A prom fwd+ IRF5 1B prom rev
Conditions: 94°C for 30 s, 40 cycles of (94°C for 15 s, 59.3°C for 1 min,
68°C for 30 s), 68°C for 5 min
Nested PCR second round: IRF5 1B prom fwd+ IRF5 1B prom rev
Conditions: 94°C for 30 s, 40 cycles of (94°C for 15 s, 66.0°C for 1 min,
68°C for 30 s), 68°C for 5 min
IRF5 1C prom fwd: TAGTgctagcGCTGGTTTCCTCAGGTCCT
IRF5 1C prom rev: CAGAagatctCAGCCCTGCCCTGGCCT
Conditions: 94°C for 30 s, 40 cycles of (94°C for 15 s, 60.8°C for 1 min,
68°C for 2 min), 68°C for 5 min
IRF5 1D prom fwd: ACATgctagCACCTGCTGCCTGTTGACC
IRF5 1D prom rev: TGGCagatctGTCATTTGACAACCCC
Conditions: 94°C for 30 s, 40 cycles of (94°C for 15 s, 59.4°C for 1 min,
68°C for 1 min), 68°C for 5 min
pGL4 sequencing fwd: CTAGCAAAATAGGCTGTCCC
*Primer annealing temperatures were 60°C for β-glucuronidase; 65°C for IRF5,
1A, and 1B; 66°C for 1C and 69°C for 1D.
† PCR for these GC-rich promoters was performed using a high-GC kit (NEB)
according to package instructions, with 10% enhancer solution included for all
reactions except exon 1D.
All are listed in 5′ to 3′ orientation. Restriction enzyme cut sites or overhangs
are indicated in lowercase. FAM, fluorescein amidite; IRF5, interferon regulatory
factor 5; RT, real time; TAMRA, carboxytetramethylrhodamine.
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